Master of Science / Department of Animal Sciences and Industry / J. Ernest Minton / It has been well documented that omega-3 PUFA (n-3 PUFA) can confer a wide variety of health benefits to humans and animals. The current study was designed to evaluate the ability of n-3 PUFA to modulate the innate immune response in two diverse breeds of horses. Ten Quarter Horse and 10 American Miniature Horse mares were assigned to either an n-3 PUFA supplemented or control diet (5 full-sized and 5 miniature mares/treatment) for 56 d. The treatment diet was designed to deliver 64.4 mg/kg BW combined eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily. Whole blood (20 mL) was collected via jugular veinipuncture into heparinized tubes on 0 d, 28 d, and 56 d. Serum PUFA analysis was conducted by gas chromatography. Peripheral blood mononuclear cell (PBMC) production of tumor necrosis factor-alpha (TNFalpha) in response to toll-like receptor (TLR) ligands lipopolysaccharide (LPS), flagellin, and lipoteichoic acid (LTA) was estimated using an equine-specific ELISA. Peripheral blood samples from d 56 were also analyzed for total and differential leukocyte counts and subjected to flow cytometric analysis. Body type did not affect basal or TLR stimulated TNFα production. Serum PUFA analysis revealed a decrease in linoleic acid (LA) and substantial increases in arachidonic acid (ARA), EPA, DHA, and docosapentaenoic acid (DPA) at both d 28 and 56 in horses fed n-3 PUFA (P less than 0.0001 for all). Dietary n-3 PUFA supplementation reduced (P less than 0.05) un-stimulated basal, but not TLR stimulated TNFalpha production by PBMC’s. Supplementation with n-3 PUFA did not affect total or differential leukocyte counts, nor selected cell surface markers. These results suggest that n-3 PUFA supplementation in the horse can modify circulating PUFA and alter the inflammatory response by reducing basal TNFalpha production. Furthermore, under conditions of the current study and considering the endpoints evaluated, the American Miniature Horse could potentially be used as a model for full-sized horse breeds.

Doctor of Philosophy / Department of Human Nutrition / Richard C. Baybutt / Weiqun George Wang / Although omega-3 fatty acids have been a hot issue in nutrition for years, there remains a paucity of research on the topic of omega-3 fatty acid and pulmonary fibrosis and the mechanism is still unclear. The purpose of this research is to investigate the preventive effects of flaxseed oil for bleomycin-induced pulmonary fibrosis in rats and to find the possible underlying mechanisms. There are two experiments demonstrated in this dissertation, one is with various doses of flaxseed oil in the diet (0, 2.5, 5, 7.5, 10, 12.5, and 15 % (w/w)), and the other is with different times of sacrificing animals after oropharyngeal bleomycin treatment (days 7 and 21). In the first study, three proteins including transforming growth factor-[beta] (TGF-[beta]), interleukin-1 (IL-1), and [alpha]-smooth muscle actin ([alpha]-SMA), commonly associated with fibrotic inflammation in the lung, were examined by Western blot and fatty acids composition of the diets and tissues were analyzed by gas chromatography (GC). Fifteen percent of flaxseed oil group significantly reduced septal and vascular thickness and fibrosis in the lung, and significant cardiac fibrosis in the heart. The amount of IL-1 and [alpha]-SMA decreased significantly as the amount of omega-3 fatty acids increased, whereas TGF-[beta] did not change significantly. The next study further reported the time-course effect and potential underlying mechanisms. Both interleukin-6 (IL-6), a protein associated with fibrotic inflammation in the lung, and renin, an enzyme related to renin-angiotensin system, were examined by Western blot. The time-dependent increase of IL-6 in response to bleomycin treatment was reversed by flaxseed oil diet. Although renin was not significantly different in the kidney, it suggested that the renin-angiotensin system may be involved locally. In addition, the profiles of fatty acids in both liver and kidney tissues as measured by lipidomics demonstrated a significant increase of omega-3: omega-6 ratio in the flaxseed oil-fed groups. Overall, these results indicated for the first time that the omega-3 fatty acids rich in flaxseed oil inhibited the formation of pulmonary fibrosis in a dose-dependent manner - however the moderate dose of flaxseed oil was most effective - via anti-inflammatory mechanisms, which appears associated with the modulated fatty acid composition in the tissues.

Omega-3 fatty acids, particularly docosahexaenoic (DHA) and eicospentaenoic acid (EPA), are important mediators for cardiovascular disease, fetal/infant development, neurological disorders and inflammatory diseases. Supplementation and washout studies are important for future research on the physiological effects of omega-3 fatty acids and for determination of the proper washout period for future cross-over studies. In this study, omega-3 fatty acid blood biomarker comparisons are made for the n-3 HUFA score (% of n-3 HUFAs in total HUFAs) and omega-3 index (sum of EPA + DHA) in plasma, erythrocytes, whole blood and a novel finger-tip prick blood method (FTPB) of analysis. This FTPB method of fatty acid analysis is further tested to determine the potential for its use in fatty acid analysis. In addition, gender differences in response to omega-3 fish oil supplementation are analyzed in all four blood fractions. Nine males and seven females were supplemented with 8 fish-oil capsules per day (providing 3.2 g/day EPA and 1.6 g/day DHA) for four weeks, followed by an eight-week omega-3 washout period. Venous plasma, erythrocyte and whole blood samples were collected during weeks 0, 4, 8 and 12 and FTPB samples were collected weekly during supplementation and washout fatty acid analysis was performed. EPA and DHA incorporation is lowest in magnitude in erythrocytes relative to all other blood fractions. Omega-3 blood biomarker comparisons demonstrate that the n-3 HUFA score is a more reliable measure across all blood fractions compared to the omega-3 index. In addition, the n-3 HUFA score demonstrates no differences (p > 0.05) between FTPB and whole blood analysis, providing evidence to support its usefulness as a tool for fatty acid analysis. However, differences (p < 0.05) do exist between these methods for saturated fatty acid, monounsaturated fatty acids, omega-6 polyunsaturated fatty acids (PUFAs) and omega-3 PUFAs. Baseline fatty acid levels for DHA, and the DHA:EPA and DHA:DPA ratios tend to be higher (p < 0.05) in females, and docosapentaenoic acid n-3 (DPAn-3) is higher (p > 0.05) in males across all blood fractions. Furthermore, a gender effect (p < 0.05) is seen for the DHA:EPA ratio across all blood fractions. At baseline, female DHA:EPA is higher (p < 0.05) than males with supplementation lowering both male and female values and removing any differences (p > 0.05) between genders. Washout results in a return of levels towards baseline, however, baseline levels are not fully reached. Furthermore, while gender differences do begin to reform during washout, these differences are not significant (p > 0.05). In conclusion, omega-3 fatty acid responses, particularly DHA:EPA ratio, demonstrate significant gender differences that may be related to differences in long-chain PUFA synthesis pathways between males and females. In addition, the n-3 HUFA score may be a more valuable omega-3 blood biomarker than the omega-3 index, as the n-3 HUFA score displays more consistent levels across all blood fractions. Finally, the FTPB method of analysis may be a useful tool in the measurement of fatty acid composition, however, some microwave methylation problems do exist, specifically in the phospholipid class of lipids.

Omega-3 fatty acids, particularly docosahexaenoic (DHA) and eicospentaenoic acid (EPA), are important mediators for cardiovascular disease, fetal/infant development, neurological disorders and inflammatory diseases. Supplementation and washout studies are important for future research on the physiological effects of omega-3 fatty acids and for determination of the proper washout period for future cross-over studies. In this study, omega-3 fatty acid blood biomarker comparisons are made for the n-3 HUFA score (% of n-3 HUFAs in total HUFAs) and omega-3 index (sum of EPA + DHA) in plasma, erythrocytes, whole blood and a novel finger-tip prick blood method (FTPB) of analysis. This FTPB method of fatty acid analysis is further tested to determine the potential for its use in fatty acid analysis. In addition, gender differences in response to omega-3 fish oil supplementation are analyzed in all four blood fractions. Nine males and seven females were supplemented with 8 fish-oil capsules per day (providing 3.2 g/day EPA and 1.6 g/day DHA) for four weeks, followed by an eight-week omega-3 washout period. Venous plasma, erythrocyte and whole blood samples were collected during weeks 0, 4, 8 and 12 and FTPB samples were collected weekly during supplementation and washout fatty acid analysis was performed. EPA and DHA incorporation is lowest in magnitude in erythrocytes relative to all other blood fractions. Omega-3 blood biomarker comparisons demonstrate that the n-3 HUFA score is a more reliable measure across all blood fractions compared to the omega-3 index. In addition, the n-3 HUFA score demonstrates no differences (p > 0.05) between FTPB and whole blood analysis, providing evidence to support its usefulness as a tool for fatty acid analysis. However, differences (p < 0.05) do exist between these methods for saturated fatty acid, monounsaturated fatty acids, omega-6 polyunsaturated fatty acids (PUFAs) and omega-3 PUFAs. Baseline fatty acid levels for DHA, and the DHA:EPA and DHA:DPA ratios tend to be higher (p < 0.05) in females, and docosapentaenoic acid n-3 (DPAn-3) is higher (p > 0.05) in males across all blood fractions. Furthermore, a gender effect (p < 0.05) is seen for the DHA:EPA ratio across all blood fractions. At baseline, female DHA:EPA is higher (p < 0.05) than males with supplementation lowering both male and female values and removing any differences (p > 0.05) between genders. Washout results in a return of levels towards baseline, however, baseline levels are not fully reached. Furthermore, while gender differences do begin to reform during washout, these differences are not significant (p > 0.05). In conclusion, omega-3 fatty acid responses, particularly DHA:EPA ratio, demonstrate significant gender differences that may be related to differences in long-chain PUFA synthesis pathways between males and females. In addition, the n-3 HUFA score may be a more valuable omega-3 blood biomarker than the omega-3 index, as the n-3 HUFA score displays more consistent levels across all blood fractions. Finally, the FTPB method of analysis may be a useful tool in the measurement of fatty acid composition, however, some microwave methylation problems do exist, specifically in the phospholipid class of lipids.

The objectives were to 1) conduct a meta-analysis to assess the association between alpha-linolenic acid (ALA) and prostate cancer; 2) analyze a trial of ALA on coronary heart disease with PSA as a post hoc outcome; 3) assess the effect of trial serum and also ALA directly on LNCaP cell growth. 1) The ALA meta-analysis of prospective and case-control studies showed no overall effect on prostate cancer. However, removal of one study from the analysis of prospective studies changed the result to a significant protective effect (RR=0.91; 95%CI:0.83,0.99). 2) No significant treatment difference was seen in the change in PSA in the randomized controlled trial. 3) The ALA treatment serum from the clinical trial did not affect LNCaP cell growth. However, ALA decreased LNCaP cell growth in a dose dependent manner when added to cell culture. The results provide no positive evidence for an effect of ALA on prostate cancer.

The objectives were to 1) conduct a meta-analysis to assess the association between alpha-linolenic acid (ALA) and prostate cancer; 2) analyze a trial of ALA on coronary heart disease with PSA as a post hoc outcome; 3) assess the effect of trial serum and also ALA directly on LNCaP cell growth. 1) The ALA meta-analysis of prospective and case-control studies showed no overall effect on prostate cancer. However, removal of one study from the analysis of prospective studies changed the result to a significant protective effect (RR=0.91; 95%CI:0.83,0.99). 2) No significant treatment difference was seen in the change in PSA in the randomized controlled trial. 3) The ALA treatment serum from the clinical trial did not affect LNCaP cell growth. However, ALA decreased LNCaP cell growth in a dose dependent manner when added to cell culture. The results provide no positive evidence for an effect of ALA on prostate cancer.

No description available.

Os ácidos graxos (AG) podem influenciar o processo secretório de insulina induzido pela glicose. Os AG &#969;3 interferem em diversos processos fisiológicos, sendo que nas ilhotas pancreáticas, os AG &#969;3 colaboram para a diminuição da lipotoxicidade induzida pelo ácido palmítico. Ao ácido palmítico são atribuídos efeitos deletérios em diversos tecidos, assim como nas células &#946;, onde ele promove a alteração da composição dos fosfolípides de membrana, do potencial elétrico da mesma e consequentemente do processo de extrusão dos grânulos de insulina. A exposição crônica das células &#946; ao excesso de ácido palmítico é tóxica, provocando diminuição da resposta secretória de insulina, redução da oxidação e captação de glicose e aumento de espécies reativas de oxigênio (EROs) que, em quantidades suprafisiológicas, irão contribuir para a falência e morte da célula &#946;. As EROs podem ser de origem mitocondrial, através do metabolismo dos nutrientes ou ainda proveniente da ativação do complexo enzimático NADPH oxidase, o qual é modulado pela glicose e pelos AG, incluindo o ácido palmítico. Em contrapartida, os AG &#969;3 exercem efeitos anti-inflamatórios e antioxidantes em diversos sistemas, contribuindo para melhora de perfil lipídico e resistência periférica à insulina. O objetivo deste trabalho foi verificar o possível efeito protetor dos AG &#969;3 contra os efeitos deletérios do ácido palmítico em células &#946; pancreáticas. Nas células &#946;, a partir dos resultados obtidos, a presença de AG &#969;3 mostrou-se eficaz para prevenir o dano secretório e o aumento de EROs, além de contribuir para manutenção da viabilidade celular e da captação de glicose nas ilhotas tratadas com ácido palmítico, desempenhando um importante papel protetor na célula &#946;. / Fatty acids (FA) may influence the process of glucose-induced insulin. The &#969;3 FA interferes in several physiological processes, and in the pancreatic islets collaborate to decrease the lipotoxicity induced by palmitic acid. Palmitic acid induces deleterious effects in several tissues, as well as in &#946; cells, where it promotes the alteration of the membrane phospholipid composition, the plasma membrane electric potential, and consequently, the process of the insulin granules extrusion. Chronic exposure of &#946; cells to high concentration of palmitic acid is toxic, leading to decreased insulin secretory response, reduced oxidation and uptake of glucose, and an increase in reactive oxygen species (ROS) which, in supraphysiological amounts, will contribute to &#946;-cell failure and death. ROS may be of mitochondrial origin, through the metabolism of nutrients or even from the activation of the enzymatic complex NADPH oxidase, which is modulated by glucose and FA, including palmitic acid. In contrast, &#969;3 FA exerts anti-inflammatory and antioxidant effects in several systems, contributing to the improvement of lipid profile and peripheral resistance to insulin. The aim of this study was verify the protective possible effect of AG &#969;3 against the deleterious effects of palmitic acid on pancreatic &#946; cells. Our results shown that the presence of &#969;3 FA was effective in preventing secretory damage and increase of EROs, also contributing to the maintenance of cell viability and glucose uptake in the islets treated with palmitic acid, playing an important &#946;-cell protective role.

Le syndrome d’apnées obstructives du sommeil (SAOS) est une pathologie caractérisée par des épisodes d’hypoxie intermittente (HI) nocturnes et est un problème de santé publique par sa prévalence dans la population générale (5-20%) et ses nombreuses complications métaboliques et cardiovasculaires. La répétition des épisodes d’HI est considérée comme le facteur principal responsable de cette morbidité cardiovasculaire dont l’athérosclérose fait partie. Le traitement de référence du SAOS par la pression positive continue présente dans certains cas une efficacité limitée, en particulier sur les conséquences cardiovasculaires qui nécessitent d’autres thérapeutiques plus spécifiques. Les mécanismes reliant SAOS et athérosclérose ne sont pas encore totalement connus. Cependant, des perturbations du métabolisme des acides gras (AG) en lien avec le processus athéromateux ont déjà été rapportées au cours du SAOS. Elles concernent en particulier le métabolisme de l’acide arachidonique (AG n-6) avec une augmentation d’eicosanoïdes pro-inflammatoires. Par ailleurs, les AG n-3 peuvent avoir une influence sur le développement et la progression des maladies cardiovasculaires, notamment grâce à une modification de la balance AG n-6 / AG n-3. Ainsi l’objectif de ce travail a donc été dans un premier temps de caractériser expérimentalement l’effet d’une supplémentation en AG n-3 sur le développement de l’athérosclérose dans le contexte d’HIC, et d’évaluer cliniquement la distribution AG n-6 / AG n-3 au niveau érythrocytaire chez des patients atteints d’un SAOS. Nous avons démontré que la supplémentation en AG n-3 permet de prévenir l’accélération de l’athérosclérose dans le contexte de l’HIC et est associée à une modulation de l’expression de certains médiateurs inflammatoires. Ces résultats prometteurs incitent à envisager une étude interventionnelle chez les patients SAOS. Dans un second temps, nous nous sommes intéressés au métabolisme des AG, via la β-oxydation mitochondriale, et aux métabolites intermédiaires produits, les acylcarnitines (ACs). Ces métabolites sont de plus en plus étudiés dans le contexte des pathologies cardiovasculaires. Nous avons étudié l’impact du SAOS sur la β-oxydation et ses conséquences sur la fonction vasculaire. L’étude de ces métabolites semble prometteuse et permettra peut-être l’émergence de marqueurs biologiques en relation avec l’état cardiovasculaire des patients. / Obstructive sleep apnea (OSA) syndrome is a disease characterized by recurrent episodes of nocturnal intermittent hypoxia (IH). OSA is a major public health problem due to its frequency in general population (5 to 20%) and its numerous metabolic and cardiovascular complications. Repetitive apneas lead to IH which is responsible of early atherosclerosis and cardiovascular complications. Gold standard treatment of OSA, that is to say continuous positive airway pressure, has poor effects on OSA cardiovascular consequences in some patients, underlining the need of alternative therapeutic strategies. Underlying mechanisms linking OSA to atherosclerosis are still poorly understood. Nevertheless, a link between polyunsaturated fatty acids (PUFAs) metabolism changes and atheromatous process has already been report during OSA syndrome. Arachidonic acid (n-6 PUFA) metabolism leads to increased biosynthesis of pro-inflammatory eicosanoids during OSA. Moreover, n-3 PUFAs influence cardiovascular complications progression especially by modifying n-6 FA / n-3 FA balance. The aim of this work was first to evaluate the influence of n-3 PUFAs supplementation on a CIH induced atherosclerosis progression model, and to clinically evaluate erythrocyte n-6 PUFA / n-3 PUFA distribution in OSA patients. We have shown that n-3 PUFAs supplementation prevents atherosclerosis acceleration in CIH exposed mice and is associated with a modulation of inflammatory mediators. These promising results encourage us to consider an interventional clinical study in OSA patients. In a second time, we have studied FA mitochondrial β-oxidation metabolism via acylcarnitines (ACs) metabolites. These ACs are increasingly studied especially in cardiovascular diseases context. OSA impact on β-oxidation metabolism and its vascular function consequences have been evaluated. ACs study is promising and will perhaps allow biological markers emergence in relation to cardiovascular pattern.

L’obésité est un facteur de risque lié à des problèmes physiques, émotionnels et comportementaux. Aujourd’hui, l’alimentation est composée d’un régime typiquement occidental «Western diet» qui est riche en acides gras saturés (AGS) et pauvre en acides gras polyinsaturés (AGPI) tel que les oméga-3 (N-3) et occasionnant un déséquilibre du ratio alimentaire N-6/N-3. Ce déséquilibre est une des causes de la prévalence des maladies mentales y compris celles des troubles de l'humeur et de l’anxiété. L’acide docosahexaénoïque (ADH, 22: 6 n-3) est l’acide gras (AG) le plus abondant dans le cerveau et son accumulation est particulièrement élevée pendant la période périnatale. Il joue un rôle important dans le développement neuronal et d'autres fonctions du cerveau tel l'apprentissage et la mémoire. Des perturbations de l’environnement périnatal peuvent influencer à très long terme l’avenir de la descendance en la rendant plus susceptible de développer des problèmes d’obésité dans un contexte nutritionnel riche. On ignore cependant si le déficit alimentaire chez la mère et particulièrement en ADH aura un impact sur la motivation alimentaire de la progéniture. L’objectif principal de cette thèse est d’étudier le rôle potentiel des N-3 sur la balance énergétique, la motivation alimentaire, la dépression et le niveau d’anxiété des descendants de souris mâles adultes assujetties à une alimentation riche en gras. Nos données ont démontré qu‘un régime maternel déficitaire en ADH durant la période périnatale incitait la descendance à fournir plus d’effort afin d’obtenir un aliment palatable. Ceci entraînerait un dérèglement de l’homéostasie énergétique en augmentant le gain de poids et en diminuant l’activité locomotrice tout en exacerbant le comportement de type anxieux dès que les souris sont exposées à un milieu obésogène. Les acides gras libres (AGL) sont des nutriments essentiels fonctionnant comme des molécules de signalisation dans le cerveau en ayant des récepteurs qui jouent un rôle important dans le contrôle du métabolisme énergétique. Parmi eux, on distingue un récepteur couplé à la protéine G (GPCR), le GPR120. Ce récepteur activé par les AGPI ω-3 intervient dans les mécanismes anti-inflammatoires et insulino-résistants via les N-3. Une mutation dans le gène GPR120 occasionnée par une réduction de l’activité de signalisation du gène est liée à l’obésité humaine. L'objectif premier de cette deuxième étude était d’évaluer l'impact de la stimulation pharmacologique de GPR120 dans le système nerveux central (SNC) sur l'alimentation, les dépenses d'énergie, le comportement de type anxieux et la récompense alimentaire. Nos résultats démontrent qu’une injection centrale aiguë d'agoniste GPR120 III réduit la prise alimentaire ad libitum et la motivation alimentaire pour un aliment riche en gras et en sucre; ainsi que les comportements de type anxieux. L’injection centrale chronique (21 jours) de ce même agoniste GPR120 III transmis par une pompe osmotique a démontré que les souris placées sous diète hypercalorique (HFD n’ont présenté aucune modification lors de la prise alimentaire ni de gain de poids mais qu’il y avait comparativement au groupe de véhicule, une réduction du comportement de type anxieux, que ce soit dans le labyrinthe en croix surélevé (LCS) ou dans le test à champ ouvert (OFT). L’ADH est reconnu pour ses propriétés anorexigènes au niveau central. De plus, la stimulation des récepteurs de GPR120 au niveau du cerveau avec un agoniste synthétique peut produire un effet intense intervenir sur le comportement lié à l'alimentation des rongeurs. Trouver une approche visant à contrôler à la fois la neuroinflammation, la récompense alimentaire et les troubles émotionnels aiderait assurément au traitement de l'obésité et du diabète de type 2. / Obesity is a risk factor for metabolic and mood disorders. The increasing abundance of the "Western diet" that is rich in saturated fatty acids (SFA) and low in polyunsaturated fatty acids (PUFA) omega-3 (N-3) can generate a physiological imbalance in the ratio of N-6/N-3 fatty acids. Such an imbalance has also been implicated in the increased prevalence of mood disorders and metabolic diseases. Docosahexaenoic acid (DHA, 22:6n-3), the most abundant fatty acid (FA) in the brain is accumulated not only during the post-natal period but also during the perinatal period. It plays an important role in neuronal development and other brain functions such as learning and memory. Disturbances of the perinatal environment can influence the sustainable future of the offspring, making it more likely to develop obesity in rich nutritional context. Some data suggest that an inadequate maternal intake of N-3 during pregnancy and the perinatal period may cause an increase in appetite signalling in the offspring as well as an increase rate of neurological and cardio-metabolic disease. It is not known if maternal dietary deficiency in N-3 will have an impact on food motivation of the offspring. The main objective of this thesis was to study the potential effect of dietary deficiency of DHA during the perinatal period on energy balance, food motivation and the anxiety-like behavior of adult male mouse offspring placed on HFD. Our data showed, as expected, that the maternal DHA deficient diet during perinatal period encouraged offspring to work harder to get a palatable food, entailed a dysregulation of energy homeostasis by increasing the body weight and reducing locomotor activity and exacerbated the anxiety-like behavior once they were exposed to an obesogenic environment. Free fatty acids (FFA) are essential nutrients that they also function as signalling molecules in the brain and have receptors that play a significant role in the control of energy metabolism. Among them is GPR120, also known as N-3 FA receptor, a g-protein coupled receptor that is reportedly activated by PUFA and shown to mediate the anti-inflammatory and insulin-sensitizing effects of N-3 FA. A mutation in the GPR120 gene that is associated with reduced GPR120 signalling activity is linked to human obesity. The objective of our second study was to test the impact of pharmacological GPR120 stimulation in the CNS on feeding, energy expenditure, anxiety-like behavior and food reward. Our results showed that an acute central injection GPR120 agonist III: reduced ad libitum food intake and the rewarding effect for high fat, high sugar food; produced a significant decrease in the anxiety-like behavior. While mice with the chronic injection (21 days) of GPR120 III agonist pump on HFD didn’t show any modification in food intake or body weight gain, but show a reduction of anxiety-like behavior in Elevated plus maze (EPM) and open-field test (OFT) compare to the vehicle group. DHA is notifies to have an anorectic action. Furthermore, stimulation of GPR120 receptors with synthetic agonist may cause an acute and profound effect on food related behavior in rodents. To find an approach that aims to control neuroinflammation, food reward and emotional disorders would greatly assist the treatment of obesity and type 2 diabetes.